JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258686

Human SMAD7 (MADH7) knockout HeLa cell lysate

Human SMAD7 (MADH7) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SMAD7 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.

別名を表示する

CRCS3, FLJ16482, MAD (mothers against decapentaplegic Drosophila) homolog 7, MAD homolog 8, MAD mothers against decapentaplegic homolog 7, MADH 7, MADH 8, MADH6, Mad homolog 7, Mothers Against Decapentaplegic Drosophila Homolog of 6, Mothers Against Decapentaplegic Drosophila Homolog of 7, Mothers against DPP homolog 7, Mothers against DPP homolog 8, Mothers against decapentaplegic homolog 7, Mothers against decapentaplegic homolog 8, SMA- AND MAD-RELATED PROTEIN 7, SMAD, SMAD family member 7, SMAD, mothers against DPP homolog 7, SMAD, mothers against DPP homolog 7 (Drosophila), SMAD7_HUMAN, hSMAD 7

1 Images
Sanger Sequencing - Human SMAD7 (MADH7) knockout HeLa cell lysate (AB258686)
  • Sanger seq

Unknown

Sanger Sequencing - Human SMAD7 (MADH7) knockout HeLa cell lysate (AB258686)

Homozygous : 1 bp insertion in exon4

Key facts

細胞タイプ

HeLa

生物種

Human

組織

Cervix

ノックアウト検証方法

Sanger Sequencing

ノックアウト変異

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.

疾病

Adenocarcinoma

製品の詳細

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

製品内容

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258686-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SMAD7 knockout HeLa cell lysate", "number":"AB258686-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258686-CMP01", "productcode":"" } ] } } }

出荷温度及び保存条件

遺伝子名
SMAD7
遺伝子編集のタイプ
Knockout
遺伝子編集の方法
CRISPR technology
ノックアウト検証方法
Sanger Sequencing
出荷温度
Ambient - Can Ship with Ice
短期保存温度
-20°C
長期保存温度
-20°C

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

MADH7 also known as SMAD7 is an intracellular protein that acts as an inhibitor in the signaling pathway of the TGF-beta (transforming growth factor-beta) family. This protein has a molecular mass of approximately 46 kDa and is widely expressed with a significant presence in tissues involved in immune response and development. SMAD7 directly interacts with receptor-regulated SMADs (R-SMADs) preventing their phosphorylation and consequent nuclear translocation effectively halting further signal transduction.
Biological function summary

SMAD7 functions to regulate the TGF-beta signaling pathway by operating as a negative feedback mediator. It binds to TGF-beta receptors recruiting E3 ubiquitin ligases which promote receptor degradation. SMAD7 is not part of complex large-scale multi-protein assemblies but is essential in modulating the pathway's activity. Its balance controls important processes like cell proliferation differentiation and apoptosis across varied biological contexts.

Pathways

SMAD7 strongly influences the TGF-beta and BMP (bone morphogenetic protein) signaling pathways. SMAD7 blocks TGF-beta signaling by interfering with the activity of R-SMADs such as SMAD2 and SMAD3 and it modulates the BMP pathway by interacting with SMAD1 and SMAD5. Its regulatory roles are tightly integrated within these pathways highlighting its importance in cellular homeostasis and response to extracellular signals.

SMAD7 has links to inflammatory conditions and cancer. Its dysregulation can lead to heightened TGF-beta signaling which may contribute to conditions like fibrosis and can enhance tumor progression by affecting cancer cell dynamics and the tumor microenvironment. In these scenarios abnormal SMAD7 function can associate with proteins such as SMAD3 in fibrosis while in cancer its association with proteins like SMAD4 disrupts normal growth control and cellular response.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

製品プロトコール

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com